Angiogenesis and Vascular Signaling

Direct overview

Angiogenesis means the growth of new blood vessels from existing ones. The body uses it in growth, healing and response to low oxygen. It is also used by tumors and by some eye diseases. A claim that a peptide "promotes angiogenesis" therefore describes a mechanism, not a benefit: whether more vessels is good or bad depends on the tissue and the person. This page is biology and evidence only, not advice.

How it works

In healthy tissue, blood vessel cells stay quiet until low oxygen or injury triggers a short burst of growth signals, including vascular endothelial growth factor (VEGF) and fibroblast growth factor. These switch on cell pathways that make vessels sprout, grow and then stabilize. Tumors use the same machinery in a disordered way, which produces leaky vessels. [1] The same review concludes that deciding when to block and when to increase angiogenesis is clinically decisive: cancers call for suppression, while some blocked-artery and degenerative problems may benefit from controlled growth. [1] With age, the ability to form new vessels declines, linked in a 2008 review to weaker oxygen-sensing signals. [2]

Increasing vessel growth: what has been tried

• Gene therapy for blocked leg arteries. A 2026 review says several studies showed biological activity and acceptable safety, but the randomized trials RAVE and TAMARIS failed to show consistent clinical benefit, illustrating the gap between promising preclinical data and human outcomes. [6] Label: insufficient evidence of benefit.
• A repair growth factor with a cancer warning. Becaplermin (Regranex) is a human platelet-derived growth factor gel. The FDA label covers diabetic foot ulcers extending into tissue below the skin that have an adequate blood supply, and states it "promotes cellular proliferation and angiogenesis". It also warns that cancers distant from the application site occurred in users in a clinical study and in post-marketing reports. [7] Label: approved medicine (FDA, specific indication); this is a protein product, not a peptide.

Promoted peptides and angiogenesis

Some research peptides are described as pro-angiogenic in animal work. BPC-157, a stable gastric pentadecapeptide (a 15-amino-acid peptide), is reported to act through VEGFR2 and nitric oxide pathways in animal models, while human data are limited to three pilot studies, so the compound is investigational. [8] A systematic review found 36 studies, 35 of them preclinical and 1 clinical, and no clinical safety data. [9]

Whether this angiogenic activity could raise tumor risk is debated in print. A published comment on one review says that review speculated about angiogenesis leading to tumor growth, and argues from animal and cell data that BPC-157 instead shows anti-tumor potential. [10] That is an argument between sets of authors, not a human study. For cancer risk of BPC-157 in people: Proper evidence not found. We checked the PubMed reviews above and the comment cited here and found no human cancer-outcome data. See the BPC-157 page and the cancer-related concerns page. Do not assume the same effect for other peptides: each compound's signaling is its own.

Who should be especially careful

Anyone with a current or past cancer, eye disease treated with VEGF blockers, wounds that are healing, or heart and blood-vessel disease should ask their clinician before considering any product said to affect blood vessels. See talking with a health professional.

Related guides

Tissue repair models and their limits, peptides and wound healing and mitochondrial signaling.